1,738
Views
4
CrossRef citations to date
0
Altmetric
Research Papers

Rational design, synthesis, and pharmacological characterisation of dicarbonyl curcuminoid analogues with improved stability against lung cancer via ROS and ER stress mediated cell apoptosis and pyroptosis

, , , , , , , , , , , , & show all
Pages 2357-2369 | Received 18 May 2022, Accepted 17 Aug 2022, Published online: 29 Aug 2022
 

Abstract

Curcumin is a natural medicine with a wide range of anti-tumour activities. However, due to β-diketone moiety, curcumin exhibits poor stability and pharmacokinetics which significantly limits its clinical applications. In this article, two types of dicarbonyl curcumin analogues with improved stability were designed through the calculation of molecular stability by density functional theory. Twenty compounds were synthesised, and their anti-tumour activity was screened. A plurality of analogues had significantly stronger activity than curcumin. In particular, compound B2 ((2E,2′E)-3,3′-(1,4-phenylene)bis(1-(2-chlorophenyl)prop-2-en-1-one)) exhibited excellent anti-lung cancer activity in vivo and in vitro. In addition, B2 could upregulate the level of reactive oxygen species in lung cancer cells, which in turn activated the endoplasmic reticulum stress and led to cell apoptosis and pyroptosis. Taken together, curcumin analogue B2 is expected to be a novel candidate for lung cancer treatment with improved chemical and biological characteristics.

Animal ethics statement

All animal care and experimental procedures were approved by the Animal Policy and Welfare Committee of the Wenzhou Medical University (Wenzhou, Zhejiang, China).

Disclosure statement

No potential conflict of interest was reported by the author(s).

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This work was supported by the Natural Science Foundation of Zhejiang Province, China [Grant Nos. LYY19H310003 and LGF21H160034]; MOE Key Laboratory of Tumour Molecular Biology, Guangdong, China [Grant No. 50411651-2020-4].